Natural product-derived PD-1 pathway blockade for Human cancer therapy: BMP4 (Bone Morphogenetic Protein 4) inhibits the expression of co-inhibitory receptor PD-1 on Antigen- Specific T-cells, increases the production of cytokines by tumor-infiltrating lymphocytes (TIL), and draining lymph nodes and augments anti-tumor activity via down-regulation of its target gene, 5/February/2017, 11.33 pm

Molecular therapy for Bone disorders: Raf kinase Inhibitor Protein (RKIP) inhibits the expression of Tgif2 and suppresses osteoporosis and bone metastasis via up-regulation of its target gene, 5/February/2017, 11.20 pm
February 5, 2017
Molecular therapy for glucose homeostasis and TIIDM: Ethyl Pyruvate (PE) increases Pax6 and insulin expression, decreases the levels of glucagon, ghrelin and Somatostatin, reduces metabolic stress, improves insulin sensitivity, promotes glucose homeostasis and prevents progression to TIIDM via down regulation of its target gene, 6/February/2017, 5.48 am
February 6, 2017
Show all

Introduction:What they say:

A recent study from Division of Infectious Diseases, School of Medicine, Johns Hopkins University, Baltimore, MD 21218, United States shows that “TGF-β1-Mediated Smad3 Enhances PD-1 Expression on Antigen-Specific T Cells in Cancer.” This study was published in the 28 September 2016 issue of Cancer Discovery (one of the best journals in Cancer Science with an impact factor of 19+) by Prof Andrea L. Cox, Park BV and others.


What we say

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Natural product-derived PD-1 pathway blockade for Human cancer therapy:  BMP4 (Bone Morphogenetic Protein 4) inhibits the expression of co-inhibitory receptor PD-1 on Antigen- Specific T-cells, increases the production of cytokines by tumor-infiltrating lymphocytes (TIL), and draining lymph nodes and augments anti-tumor activity via down-regulation of its target gene


What is known?

It has recently been shown that blocking PD-1 with antibodies one could make tumors shrink. This work, relating to Cancer immunotherapy, has been chosen as Science’s breakthrough of the year recently.


From Research Findings to Therapeutic opportunity: 

This suggests that BMP4, by decreasing the expression of its target gene, it may suppress the expression of PD-1. Thereby, it may (1) increase the production of cytokines by tumor-infiltrating lymphocytes (TIL), and draining lymph nodes; (2) augment antitumor activity of the immune system; & (3) inhibit metastatic cancer progression.

price-100

[easy_payment currency=”USD”]Thus, pharmacological formulations encompassing “BMP4 activators or BMP4 activators in combination with other drugs may be used to inhibit the progression of tumors.


Details of the research findings:

Idea Proposed/Formulated (with experimental evidence) by: Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Amount: $100

Undisclosed information: How BMP4  suppresses the expression of PD-1 and augments anti-tumor immunity

# Research cooperation

For payment and purchase, you may reach us at info@genomediscovery.org


References

Citation: Boominathan, L., Natural product-derived PD-1 pathway blockade for Human cancer therapy:  BMP4 (Bone Morphogenetic Protein 4) inhibits the expression of co-inhibitory receptor PD-1 on Antigen- Specific T-cells, increases the production of cytokines by tumor-infiltrating lymphocytes (TIL), and draining lymph nodes and augments anti-tumor activity via down-regulation of its target gene, 5/February/2017, 11.33 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Web: http://genomediscovery.org or http://newbioideas.com

Courtesy: When you cite drop us a line at info@genomediscovery.org


Comments are closed.